An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab

N Engl J Med. 2003 Dec 25;349(26):2570-2; discussion 2570-2. doi: 10.1056/NEJM200312253492622.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alemtuzumab
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / adverse effects*
  • Antineoplastic Agents / adverse effects*
  • Female
  • Herpesvirus 4, Human / isolation & purification*
  • Humans
  • Leukemia, T-Cell / drug therapy
  • Lymphocyte Count
  • Lymphoproliferative Disorders / chemically induced*
  • Lymphoproliferative Disorders / virology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antineoplastic Agents
  • Alemtuzumab